S. O'Reilly

发表

Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.

C. Caldas, E. Provenzano, J. Abraham, 2017, The Lancet. Oncology.

Sources of error in tissue and tumor measurements of 5-[18F]fluorouracil.

P. Price, J. Matthews, R. Harte, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity.

E. Perez, S. Chan, J. Hamm, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics].

V. Moiseenko, T. Griffin, R. Gordon, 2000, Voprosy onkologii.

Reducing febrile neutropenia rates in early breast cancer. Experience of two UK cancer centres

A. Mullard, V. Misra, S. O'Reilly, 2014, Supportive Care in Cancer.

Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study

P. Clark, D. Smith, H. Innes, 2003, British Journal of Cancer.

Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines

H. Burger, D. Talbot, D. Talbot, 2002, British Journal of Cancer.

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

H. Earl, D. Rea, S. M. Crawford, 2006, The New England journal of medicine.

Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival.

R. Rubens, M. Richards, S. O’Reilly, 1990, European journal of cancer.

Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography:a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas

H Evans, E S Newlands, P. Price, 2000, British Journal of Cancer.

Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland

C. Quinn, B. Hennessy, M. Keane, 2015, Breast Cancer Research and Treatment.

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

E. Perez, Y. Chia, J. Hamm, 2013, The Lancet. Oncology.

Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.

S. Osman, P. Price, T. Jones, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significant efficacy in a phase 2 study of NKTR-102, a novel polymer conjugate of Irinotecan, in patients with pre-treated metastatic breast cancer (MBC)

E. Perez, J. Hamm, A. Awada, 2010 .